Professional Bio
Dr. Berk is Professor of Medicine, Cardiology, and Pharmacology and the Senior Vice President for Health Sciences at the University of Rochester. Dr. Berk received his M.D. and Ph.D. degrees from the University of Rochester. He has served on the faculties of Harvard Medical School, Emory University, and the University of Washington. Dr. Berk was previously Chairman of Medicine (1999-2006) and Chief of the Cardiology Unit (1998-2003) at the University of Rochester. In addition he was Director of the Aab Cardiovascular Research Institute. Dr. Berk is a fellow of the American Heart Association and the American College of Cardiology, and a member of the Association of American Physicians. Dr. Berk is past-president of the North American Vascular Biology Organization (NAVBO). He is Consulting Editor for Circulation and Circulation Research and is on the editorial boards of ATVB and the Journal of Clinical Investigation. He serves on the Empire State Stem Cell Board Funding Committee and the National Heart, Lung and Blood Institute (NHLBI), Stem Cell Clinical Trial Network and Gene and Cell-Based Therapies Data and Safety Monitoring Board (DSMB).
His research interests include: molecular biology of renin-angiotensin-aldosterone
system; regulation of endothelial cell function especially by shear stress; the role of oxidative stress in vascular biology and the genetic mechanisms of vascular remodeling. Dr. Berk has published widely – more than 250 articles, chapters, and books.
Listed below is Dr. Berk's affiliation:
Bradford C. Berk, M.D., Ph.D.
Professor of Medicine, Cardiology, and Pharmacology
Senior Vice President for Health Sciences
University of Rochester Medical Center
Rochester, New York
US Postal mail should be sent to:
Bradford C. Berk, M.D., Ph.D.
University of Rochester Medical Center
Office of Vice President for Health Sciences
601 Elmwood Avenue, Box 706
Rochester, New York 14642
FEDEX
Bradford C. Berk, M.D, Ph.D.
University of Rochester Medical Center
Office of Vice President for Health Sciences
601 Elmwood Avenue, Box 706, Rm. 1-4337
Rochester, NY 14642
Research Bio
Dr. Berk's laboratory is known for studying signal transduction mechanisms in the vasculature, focusing specifically on defining the mechanisms by which cells in the vascular wall respond to hemodynamic and hormonal stimuli. The four major research areas ongoing in the laboratory include 1) Mechanisms by which blood vessels sense changes in blood flow using protein kinases as targets for signal events. Using cultured endothelial cells and animal models of altered blood flow two projects are underway. The first project investigates the mechanisms by which flow activates the Big MAP kinase (or ERK5) and inhibits inflammation and atherosclerosis.
In the second project, the redox-dependent mechanisms that maintain an antioxidant environment are being studied using the apoptosis signal kinase-1 (ASK1) and thioredoxin as targets. The goal of these projects is to identify signal transduction events that confer atheroprotection in the setting of steady laminar flow as opposed to the pro-atherosclerotic effects of disturbed and turbulent flow. 2) The cellular mechanisms that cause hypertension are being investigated by analysis of the role of the renin angiotensin system and the kinases that regulate intracellular sodium. The regulation of smooth muscle cell growth by angiotensin II is focused on the activation of intracellular kinases and phosphatases by the angiotensin II receptor. 3) The mechanisms by which changes in cellular redox state alter blood vessel function are being studied to provide insight into the ways that reactive oxygen species regulate vessel function. Specifically the role of the chaperone molecule cyclophilin A as a mediator of vascular pathology is being studied with several different transgenic models. 4) A genetic model of vascular remodeling in the mouse has been established. A carotid flow reduction model has been characterized and is being used to identify genes responsible for impaired flow-dependent remodeling by positional cloning in inbred strains of mice.
| Vice-chair | Vascular Cell Biology Gordon Conference |
2004 - 2005 |
| Russell Ross Memorial Lectureship in Vascular Biology | Council for Arteriosclerosis, Thrombosis, Vascular Biology |
2003 |
| Theo Tsagaris Memorial Lecture | University of Utah | Salt Lake City, Utah |
2002 |
| Indiana Vascular Society/ICVBM Conference | University of Indiana | Indianapolis, Indiana |
2002 |
| Pfizer Visiting Professor | University of Iowa | Iowa City, Iowa |
2002 |
| Borun Visiting Professor in Cardiology | UCLA Medical Center | Los Angeles, CA |
1999 |
| Annual Pulsifer Lecture, Guest Speaker | Rochester Academy of Medicine |
1999 |
| Pfizer Visiting Professor of Cardiovascular Disease | Wayne State University School of Medicine |
1995 |
| Marion Young Scholar Award | American Society for Hypertension |
1992 |
| Katz Prize Finalist | American Heart Association |
1986 |
| Young Investigator's Award | American College of Cardiology |
1985 |
| Robert Kates Memorial Prize in Research, Doran J. Stephens Prize in Medicine | Alpha Omega Alpha |
1981 |
| Phi Beta Kappa, John Albree Jr. Class of 1981 Memorial Fund Award for History | John Woodruff Simpson Postgraduate Scholarship in Medicine |
1975 |
| Medical Scientist Training Program (Pharmacology) | University of Rochester | Rochester, NY |
1975 - 1981 |
| Woods Hole Oceanographic Institution Fellowship (Microbiology) | Woods Hole Oceanographic Institute | Woods Hole, MA |
1974 |
Thioredoxin Interacting Protein (TXNIP or VDUP1) as a Regulator of Vascular Function
United States Serial NO.: 11/814,442
Filed Date: January 20, 2006
Title: Thioredoxin Interacting Protein (TXNIP) as a Regulator of Vascular Function
Invented by: Bradford Berk
|
Thioredoxin Interacting Protein (TXNIP or VDUP1) as a Regulator of Vascular Function
United States Serial NO.: 2006206376
Filed Date: January 20, 2006
Title: Thioredoxin Interacting Protein (TXNIP as Regulator of Vascular Function
Invented by: Bradford Berk
|
A Novel Anti-Inflammatory Agent for the Treatment of Inflammatory Diseases
United States Serial NO.: 12/678,352
Filed Date: September 16, 2008
Title: Method and Compositions For Treatment or Prevention of Inflammatory Conditions
Invented by: Chen Yan, Jian-Dong Li, Kye-Im Jeon, Xiangbin Xu, Bradford Berk
|
A Novel Anti-Inflammatory Agent for the Treatment of Inflammatory Diseases
United States Serial NO.: 200880117461.X
Filed Date: September 16, 2008
Title: Method and Compositions for Treatment or Prevention of Inflammatory Conditions
Invented by: Chen Yan, Jian-Dong Li, Kye-Im Jeon, Xiangbin Xu, Bradford Berk
|
A Novel Anti-Inflammatory Agent for the Treatment of Inflammatory Diseases
United States Serial NO.: 14/191,219
Filed Date: February 26, 2014
Title: Method and Compositions For Treatment or Prevention of Inflammatory Conditions
Invented by: Chen Yan, Jian-Dong Li, Kye-Im Jeon, Xiangbin Xu, Bradford Berk
|
A Novel Anti-Inflammatory Agent for the Treatment of Inflammatory Diseases
United States Serial NO.: 14/970,028
Filed Date: December 15, 2015
Title: Method and Compositions For Treatment or Prevention of Inflammatory Conditions
Invented by: Chen Yan, Jian-Dong Li, Kye-Im Jeon, Xiangbin Xu, Bradford Berk
|
GIT1 Ankyrin Repeat Domain (GIT1ANK) is a Novel Drug Target of Regulating Angiogenesis
United States Serial NO.: 14/775,936
Filed Date: March 14, 2014
Title: GIT1 Ankyrin Repeat Domain (GIT1ANK) is a Novel Drug Target of Regulating Angiogenesis
Invented by: Bradford Berk, Jinjiang Pang, Syamantak Majumder
|
2016 Sep 1
Heo KS, Berk B, Abe JI. "Disturbed Flow-Induced Endothelial Proatherogenic Signaling Via Regulating Post-Translational Modifications and Epigenetic Events." Antioxidants & redox signaling. 2016 Sep 1; 25(7):435-50. Epub 2016 Apr 05. |
2016 Jun 1
Perrucci GL, Straino S, Corlianò M, Scopece A, Napolitano M, Berk BC, Lombardi F, Pompilio G, Capogrossi MC, Nigro P. "Cyclophilin A modulates bone marrow-derived CD117(+) cells and enhances ischemia-induced angiogenesis via the SDF-1/CXCR4 axis." International journal of cardiology. 2016 Jun 1; 212:324-35. Epub 2016 Mar 24. |
2016 Mar
Shi X, O'Neill MM, MacDonnell S, Brookes PS, Yan C, Berk BC. "The RSK Inhibitor BIX02565 Limits Cardiac Ischemia/Reperfusion Injury." Journal of cardiovascular pharmacology and therapeutics. 2016 Mar; 21(2):177-86. Epub 2015 Jun 30. |
2015 May 22
Simons M, Alitalo K, Annex BH, Augustin HG, Beam C, Berk BC, Byzova T, Carmeliet P, Chilian W, Cooke JP, Davis GE, Eichmann A, Iruela-Arispe ML, Keshet E, Sinusas AJ, Ruhrberg C, Woo YJ, Dimmeler S. "State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization: A Scientific Statement From the American Heart Association." Circulation research. 2015 May 22; 116(11):e99-132. Epub 2015 Apr 30. |
2015 May 10
Burke R, Berk B. "The Role of PB1 Domain Proteins in Endothelial Cell Dysfunction and Disease." Antioxidants & redox signaling. 2015 May 10; 22(14):1243-56. Epub 2015 Mar 23. |
